Optimisation of immunofluorescence methods to determine MCT1 and MCT4 expression in circulating tumour cells.
Kershaw, Stephen Cummings, Jeffrey Morris, Karen Tugwood, Jonathan D
Kershaw, Stephen
Cummings, Jeffrey
Morris, Karen
Tugwood, Jonathan D
Citations
Altmetric:
Abstract
The monocarboxylate transporter-1 (MCT1) represents a novel target in rational anticancer drug design while AZD3965 was developed as an inhibitor of this transporter and is undergoing Phase I clinical trials ( http://www.clinicaltrials.gov/show/NCT01791595 ). We describe the optimisation of an immunofluorescence (IF) method for determination of MCT1 and MCT4 in circulating tumour cells (CTC) as potential prognostic and predictive biomarkers of AZD3965 in cancer patients.
Description
Date
2015
Publisher
Collections
Keywords
Type
Article
Citation
Optimisation of immunofluorescence methods to determine MCT1 and MCT4 expression in circulating tumour cells. 2015, 15:387 BMC Cancer